Treatment response to Aricept® (donepezil hydrochloride) not predicted by Apolipoprotein E4 genotype or gender
A study of 286 patients with mild to moderate Alzheimer's disease found that treatment response to Aricept was not predicted by ApoE4 genotype or gender. Patients treated with Aricept showed significant improvements in global function and cognition, while those on placebo experienced decline.